RA Capital Management Bets Another $20 Million On Kala Pharmaceuticals Inc.
Peter Kolchinsky’s RA Capital purchased $20 million of Kala Pharmaceuticals Inc. (KALA) shares. The details of the transaction can be seen below......(read more)
Posts Tagged ‘Hedge Fund:307’
This Biotech Investor’s Picks Returned 31% in Q1; Here Are Its New Bets
Peter Kolchinsky is one of the best biotech investors and many of his stock picks generate strong returns. We calculate a fund’s returns by taking......(read more)
13D Filing: RA Capital Management and Biocryst Pharmaceuticals Inc (BCRX)
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
13D Filing: RA Capital Management and Solid Biosciences Inc (SLDB)
Solid Biosciences Inc (NASDAQ:SLDB): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’......(read more)
Big Insider Buying at Hot IPO Solid Biosciences (SLDB), Range Resources (RRC) and General Electric (GE)
With the stock market having been battered in recent days and fears that a large correction may be starting to pick up steam becoming more pronounced,......(read more)
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
13G Filing: RA Capital Management and Scpharmaceuticals Inc (SCPH)
Scpharmaceuticals Inc (NASDAQ:SCPH): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’......(read more)
13G Filing: RA Capital Management and Inflarx NV (IFRX)
Inflarx NV (NASDAQ:IFRX): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’s latest......(read more)
13D Filing: RA Capital Management and Wave Life Sciences Ltd (WVE)
Wave Life Sciences Ltd (NASDAQ:WVE): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’......(read more)
13G Filing: RA Capital Management and Sunesis Pharmaceuticals Inc (SNSS)
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
13D Filing: RA Capital Management and Kalvista Pharmaceuticals Inc. (KALV)
Kalvista Pharmaceuticals Inc. (NASDAQ:KALV): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 9 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE......(read more)
Avexis Inc. (AVXS): RA Capital Management Ups Its Stake
Peter Kolchinsky‘s RA Capital Management has slightly raised its stake in Avexis Inc. (NASDAQ:AVXS), as per a new Form 13G with the Securities......(read more)
RA Capital Management Slashes Alcobra Ltd (ADHD) Position After FDA Clinical Hold
Peter Kolchinsky‘s RA Capital Management has slashed its position in Alcobra Ltd (NASDAQ:ADHD) to just under 1.31 million shares according to a......(read more)
Aclaris Therapeutics Inc (ACRS): RA Capital Management Disposes of 1.1 Million Shares
An amended 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has sold around 1.1 million shares of Aclaris Therapeutics......(read more)
Protagonist Therapeutics Inc (PTGX): RA Capital Management Acquires 6.8% Stake
Peter Kolchinsky‘s RA Capital Management reported via a recent 13G filing with the SEC that it has taken a new position in a company that has recently......(read more)
RA Capital’s Top Q2 Performers; Predicts Big Things Ahead for Pharma Stocks
RA Capital Management LLC is a crossover fund manager that invests in public and private healthcare and life science companies developing drugs, medical......(read more)
Vitae Pharmaceuticals Inc (VTAE): RA Capital Management Ups Its Stake
A recent 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has acquired more shares of Vitae Pharmaceuticals Inc......(read more)
Ardelyx (ARDX): RA Capital Management Boosts Stake to 7.7%
Peter Kolchinsky‘s RA Capital Management has stepped up its interest in Ardelyx Inc. (NASDAQ:ARDX). As reported in a recent filing with the Securities......(read more)
Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. (ACHN), Wave Life Sciences (WVE) & More Heading Into 2016
Peter Kolchinsky founded RA Capital Management in 2001 and focuses mainly on healthcare stocks. One of the few hedge fund managers who actually holds......(read more)
13G Filing: RA Capital Management and Derma Sciences, Inc. (DSCI)
In a new filing with the Securities and Exchange Commission, Peter Kolchinsky‘s RA Capital Management disclosed a position in Derma Sciences Inc......(read more)
Dalton Investments Proposes 6-Point Action Plan to Eros, While Eminence Capital Reveals New Stake in This Hotel Operator
The practice of monitoring quarterly 13F filings has become more popular in recent years, which led to several exchange traded funds (ETFs) being launched......(read more)
Two Activist Plays And Two Biotech Moves You Should Check Out
With hedge funds having submitted their 13F filings for the third quarter, people at Insider Monkey are busy compiling the data necessary to identify......(read more)
Sequenom, Aclaris, and Xenoport Making Waves Among Elite Healthcare Investors
Three prominent healthcare-focused funds that we track at Insider Monkey submitted filings with the SEC today, disclosing new or bulked up positions in......(read more)
Is Zogenix A Good Stock To Buy Now?
RA Capital Management, led by Peter Kolchinsky, has disclosed a massive new stake in California-based pharmaceutical company Zogenix, Inc (NASDAQ:ZGNX......(read more)
Steve Cohen, Peter Kolchinsky Disclose New Stakes In Micro-cap Pharmaceutical Stocks
Steve Cohen’s Point72 Asset Management has initiated a new position in Inotek Pharmaceuticals Corporation (NASDAQ:ITEK). In a freshly-submitted filing......(read more)
Peter Kolchinsky’s New Top Healthcare Pick And Old Favorites
Peter Kolchinsky‘s RA Capital Management recently filed its 13F with the SEC for the reporting period of June 30. Peter Kolchinsky started RA Capital......(read more)
RA Capital’s Latest Move In Alcobra Ltd (ADHD) Coming Off Hefty Second Quarter Gains
According to a recent filing with the Securities and Exchange Commission, Peter Kolchinsky‘s RA Capital has initiated a position in Alcobra Ltd (......(read more)
RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech
The biotechnology industry is up by more than 50% over the last year, but these towering returns don’t come without great risk and volatility. However......(read more)
Ardelyx Inc (ARDX): RA Capital Management Discloses 7.3% Passive Stake
RA Capital Management, led by Peter Kolchinsky, has opened a new position in clinical-stage biopharmaceutical company Ardelyx Inc (NASDAQ:ARDX). A new......(read more)
Bitauto Hldg Ltd (ADR) (BITA), Aurinia Pharmaceuticals Inc (AUPH): Tiger Global and RA Capital Disclose Their Latest Moves
In a new filing with the Securities and Exchange Commission, Billionaire Chase Coleman‘s Tiger Global disclosed slightly reducing its exposure......(read more)
Regulus Therapeutics Inc (RGLS), Trevena Inc (TRVN), Juno Therapeutics Inc (JUNO): RA Capital’s Top New Biotech Picks
Peter Kolchinsky’s RA Capital Management filed its latest 13F with the Securities and Exchange Commission in February, and we’ve gone through the......(read more)
Tekmira Pharmaceuticals Corporation (TKMR): RA Capital Management Discloses 10% Passive Stake
It was revealed in a filing yesterday with the U.S Securities and Exchange Commission that RA Capital Management has opened a large, passive position......(read more)
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James E. Flynn and Peter Kolchinsky Think These Stocks Look Healthy
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E. Flynn’s Deerfield Management and......(read more)
The Medicines Company (MDCO), TG Therapeutics Inc (TGTX): Bridger Management & Ra Capital Management Taking Plunge
In the last few days, we have seen a lot of capital from funds that we track getting shifted to pharmaceutical stocks and no it’s not just sector specific......(read more)
CIG Wireless Corp (CIGW), Achillion Pharmaceuticals Inc (ACHN): Jeffrey Tannenbaum And Peter Kolchinsky Disclose Their Latest Moves
CIG Wireless Corp (OTCBB:CIGW), an operator of wireless and broadcast communication towers in the United States, has issued approximately 1.25 million......(read more)
Achillion Pharmaceuticals Inc (ACHN), Tenax Therapeutics Inc (TENX): Peter Kolchinsky’s Latest Equity Moves
RA Capital Management has continued the sale of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares. In a recent wave of reductions, the fund has dumped......(read more)
Achillion Pharmaceuticals, Inc. (ACHN): RA Capital Management Sells Over 2 Million Shares
RA Capital Management, managed by Peter Kolchinsky, continues to unload its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In a new filing with......(read more)
Achillion Pharmaceuticals, Inc. (ACHN): Peter Kolchinsky’s RA Capital Sells Some More Shares
Peter Kolchinsky‘s RA Capital Management, in a new filing with the Securities and Exchange Commission, has disclosed the sale of around 1.70 million......(read more)
RA Capital Management Continues To Unload Achillion Pharmaceuticals, Inc. (ACHN) Stock: Sells Further 835,293 Shares
In a new filing with the U.S. Securities and Exchange Commission, RA Capital Management, managed by Peter Kolchinsky, has disclosed holding an 18.1% passive......(read more)
Hedge Fund News: Crispin Odey, Peter Kolchinsky & T Boone Pickens
Manchester United Divides Hedge Funds’ Loyalties (WSJ) Some of Europe’s most powerful hedge fund managers are sharply divided on the outlook......(read more)
Hedge Fund Highlights: Ken Griffin, Paul Tudor Jones & Bill Ackman
Citadel’s Griffin Defends HFT (FINalternatives) Citadel Investment Group founder Kenneth Griffin yesterday urged Congress not to ban high-frequency......(read more)
RA Capital Management Sells 800,000 Shares of Achillion Pharmaceuticals Inc. (ACHN)
RA Capital Management, managed by Peter Kolchinsky, has sold 800,000 shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) in two transactions for about......(read more)
RA Capital Reports New 5.8% Position In Recently Public Versartis Inc (VSAR)
Peter Kolchinsky’s RA Capital Management has initiated a new position in Versartis Inc (NASDAQ:VSAR). RA Capital owns 1.40 million shares of the company......(read more)
Ra Capital Management Reveals New Stake in Enanta Pharmaceuticals Inc (ENTA)
Peter Kolchinsky‘s Ra Capital Management disclosed a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). According to a 13G filing, the......(read more)
RA Capital Management Discloses New Stake in SANUWAVE Health Inc. (SNWV); Boosts Position in pSivida Corp. (PSDV)
In two recent filings with the U.S. Securities and Exchange Commission, Peter Kolchinsky’s RA Capital Management has revealed a new position in SANUWAVE......(read more)
RA Capital Discloses New Passive Stake in Repros Therapeutics Inc (RPRX)
RA Capital Management, managed by Peter Kolchinsky, has revealed a new position in Repros Therapeutics Inc (NASDAQ:RPRX). RA Capital has disclosed a passive......(read more)
